about
Xenobiotic acceleration of idiopathic systemic autoimmunity in lupus-prone bxsb miceChronic morphine induces up-regulation of the pro-apoptotic Fas receptor and down-regulation of the anti-apoptotic Bcl-2 oncoprotein in rat brainAntiapoptotic Effects of EGb 761Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologicallyAnalysis of gene profile, steady state proliferation and apoptosis of double-negative T cells in the periphery and gut epithelium provides new insights into the biological functions of the Fas pathway.Importance of reverse signaling of the TNF superfamily in immune regulation.Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung.The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.Modulation of Fas-induced apoptosis by p75 neurotrophin receptor in a human neuroblastoma cell line.New complex Ad vectors incorporating both rtTA and tTS deliver tightly regulated transgene expression both in vitro and in vivo.CD44 variant isoform v10 is expressed on tumor-infiltrating lymphocytes and mediates hyaluronan-independent heterotypic cell-cell adhesion to melanoma cells.Anaplastic and atypical meningiomas express high levels of Fas and undergo apoptosis in response to Fas ligation.Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.High-dose glucose-insulin-potassium treatment reduces myocardial apoptosis in patients with acute myocardial infarction.Impairment of Fas-ligand-caveolin-1 interaction inhibits Fas-ligand translocation to rafts and Fas-ligand-induced cell death.Serum Fas and Bcl-2 in patients with epilepsy.
P2860
Q24812899-94451C32-BF54-457A-BDBC-ABF23D723F3BQ28363748-95A628DA-1C9D-4612-B0DF-8703AFCC7CA9Q28387384-007DB56C-E4CB-474C-BC56-248DDDE3F5BFQ35209364-E87CF3C7-5534-434E-9BDA-B893C26594E5Q35928288-745F723B-2CB1-4FF8-A53E-EF01761BEE0DQ37672419-844AF234-7198-4615-B94A-981DCA5DD409Q38096027-16847D24-EFF3-44C0-A28C-6B67D9371903Q39594251-B7B2796A-2EAC-4061-8738-29C2E805AA2FQ39855538-51ED6E2E-D40A-4287-BC17-04B189A3BB5CQ40363690-1940755A-0BE9-48F5-AEA0-403A1F6BE331Q40468763-67885A62-D994-4271-98F4-A583EE601A3EQ40654295-31691D6A-7574-4A08-BCCE-56AD2F97E08EQ42856233-F9E0BDE7-39BA-478A-ADAA-37317CE3E75DQ43761459-489C498D-BFE6-4506-8433-3C26DBE7342FQ45283828-E3204859-A39E-44F0-88CC-C6474E78D2DCQ48191024-53310EBB-735F-4D80-ADBD-9F8E5BD87893Q54344575-1E177D14-4FF8-4B40-974A-B790929BC92A
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Structure and function of Fas/Fas ligand.
@ast
Structure and function of Fas/Fas ligand.
@en
type
label
Structure and function of Fas/Fas ligand.
@ast
Structure and function of Fas/Fas ligand.
@en
prefLabel
Structure and function of Fas/Fas ligand.
@ast
Structure and function of Fas/Fas ligand.
@en
P2093
P2860
P1476
Structure and function of Fas/Fas ligand.
@en
P2093
Orlinick JR
Vaishnaw AK
P2860
P304
P356
10.3109/08830189909088485
P577
1999-01-01T00:00:00Z